Cargando…

Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making

It is no coincidence that the reports of two meetings, one organized by the US Food and Drug Administration (FDA), in March 2014, and the other by the UK Medicines and Healthcare Products Regulatory (MHRA), in collaboration with ABPI (the Association of British Pharmaceutical Industry), in June 2014...

Descripción completa

Detalles Bibliográficos
Autores principales: Rowland, M, Lesko, LJ, Rostami-Hodjegan, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505824/
https://www.ncbi.nlm.nih.gov/pubmed/26225258
http://dx.doi.org/10.1002/psp4.52
_version_ 1782381591459266560
author Rowland, M
Lesko, LJ
Rostami-Hodjegan, A
author_facet Rowland, M
Lesko, LJ
Rostami-Hodjegan, A
author_sort Rowland, M
collection PubMed
description It is no coincidence that the reports of two meetings, one organized by the US Food and Drug Administration (FDA), in March 2014, and the other by the UK Medicines and Healthcare Products Regulatory (MHRA), in collaboration with ABPI (the Association of British Pharmaceutical Industry), in June 2014, have been published in tandem in CPT-PSP.12 Both reports deal with the same topic, namely, the impact of physiologically based pharmacokinetics (PBPK) in clinical drug development and the best practices for such applications. This reflects the transition of PBPK from academic curiosity to industrial norm, manifested by the regulatory agencies encouraging its use and receiving an increasing number of submissions containing PBPK models. The goal of both meetings was to help determine the need and facilitate the development of regulatory guidances on this subject within the conceptual framework of model informed drug development and regulatory decision-making. A further reflection of this intent is the publication by the European Medicines Agency of a Concept Paper on PBPK.3 One is reminded of a similar train of events surrounding the introduction of population PK/PD and nonlinear mixed effects modeling in the early-late 1990s, again with encouragement and receptivity of regulatory agencies leading to FDA guidance on the topic.4 Indeed, the intention of PBPK modeling and simulation is to complement other approaches, such as compartmental modeling, or, in some cases, replace them with a more mechanistic approach. PBPK models represent an important class of models that characterize absorption, distribution, metabolism, excretion (ADME) processes and their underlying biological and physiological drivers. An increased understanding of these drivers and their unique interactions with drug substance and formulation factors provides critical insights into how drugs will behave in healthy volunteers and patients with disease.
format Online
Article
Text
id pubmed-4505824
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-45058242015-07-22 Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making Rowland, M Lesko, LJ Rostami-Hodjegan, A CPT Pharmacometrics Syst Pharmacol Editorial It is no coincidence that the reports of two meetings, one organized by the US Food and Drug Administration (FDA), in March 2014, and the other by the UK Medicines and Healthcare Products Regulatory (MHRA), in collaboration with ABPI (the Association of British Pharmaceutical Industry), in June 2014, have been published in tandem in CPT-PSP.12 Both reports deal with the same topic, namely, the impact of physiologically based pharmacokinetics (PBPK) in clinical drug development and the best practices for such applications. This reflects the transition of PBPK from academic curiosity to industrial norm, manifested by the regulatory agencies encouraging its use and receiving an increasing number of submissions containing PBPK models. The goal of both meetings was to help determine the need and facilitate the development of regulatory guidances on this subject within the conceptual framework of model informed drug development and regulatory decision-making. A further reflection of this intent is the publication by the European Medicines Agency of a Concept Paper on PBPK.3 One is reminded of a similar train of events surrounding the introduction of population PK/PD and nonlinear mixed effects modeling in the early-late 1990s, again with encouragement and receptivity of regulatory agencies leading to FDA guidance on the topic.4 Indeed, the intention of PBPK modeling and simulation is to complement other approaches, such as compartmental modeling, or, in some cases, replace them with a more mechanistic approach. PBPK models represent an important class of models that characterize absorption, distribution, metabolism, excretion (ADME) processes and their underlying biological and physiological drivers. An increased understanding of these drivers and their unique interactions with drug substance and formulation factors provides critical insights into how drugs will behave in healthy volunteers and patients with disease. John Wiley & Sons, Ltd 2015-06 2015-06-15 /pmc/articles/PMC4505824/ /pubmed/26225258 http://dx.doi.org/10.1002/psp4.52 Text en © 2015 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Editorial
Rowland, M
Lesko, LJ
Rostami-Hodjegan, A
Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making
title Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making
title_full Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making
title_fullStr Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making
title_full_unstemmed Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making
title_short Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making
title_sort physiologically based pharmacokinetics is impacting drug development and regulatory decision making
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505824/
https://www.ncbi.nlm.nih.gov/pubmed/26225258
http://dx.doi.org/10.1002/psp4.52
work_keys_str_mv AT rowlandm physiologicallybasedpharmacokineticsisimpactingdrugdevelopmentandregulatorydecisionmaking
AT leskolj physiologicallybasedpharmacokineticsisimpactingdrugdevelopmentandregulatorydecisionmaking
AT rostamihodjegana physiologicallybasedpharmacokineticsisimpactingdrugdevelopmentandregulatorydecisionmaking